Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 29, Issue 23, 2011, Pages 3185-3193

  Hof, Jana ^a   Krentz, Stefanie ^a   Van Schewick, Claudia ^a   Körner, Gabriele ^a   Shalapour, Shabnam ^a   Rhein, Peter ^a   Karawajew, Leonid ^a   Ludwig, Wolf Dieter ^b   Seeger, Karl ^a   Henze, Günter ^a   Von Stackelberg, Arend ^a   Hagemeier, Christian ^a   Eckert, Cornelia ^a   Kirschner Schwabe, Renate ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Helios Hospital Berlin Buch   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RELAPSE; CELL CYCLE; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; DOWN SYNDROME; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE DELETION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTICENTER STUDIES AS TOPIC; MUTATION; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051828388     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.8144     Document Type: Article

References (36)

1. Möricke A., Zimmermann M., Reiter A., et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010
2. Salzer W.L., Devidas M., Carroll W.L., et al: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children's Oncology Group. Leukemia 24:355-370, 2010
3. Einsiedel H.G., Von Stackelberg A., Hartmann R., et al: Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 23:7942-7950, 2005 (Pubitemid 46657394)
4. Tallen G., Ratei R., Mann G., et al: Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90. J Clin Oncol 28:2339-2347, 2010
5. Parker C., Waters R., Leighton C., et al: Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial. Lancet 376:2009-2017, 2010
6. Henze G., Stackelberg A.: Relapsed acute lymphoblastic leukemia, in Pui C.-H. (ed): Childhood Leukemias. Cambridge, United Kingdom, Cambridge University Press, 2006
7. Eckert C., Biondi A., Seeger K., et al: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358:1239-1241, 2001 (Pubitemid 33010852)
8. Aas T., Børresen A.L., Geisler S., et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996 (Pubitemid 26225099)
9. Poeta M.L., Manola J., Goldwasser M.A., et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552-2561, 2007 (Pubitemid 350294222)
10. Wattel E., Preudhomme C., Hecquet B., et al: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157, 1994
11. Haferlach C., Dicker F., Herholz H., et al: Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 22:1539-1541, 2008
12. Zenz T., Eichhorst B., Busch R., et al: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479, 2010
13. Wada M., Bartram C.R., Nakamura H., et al: Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82:3163-3169, 1993 (Pubitemid 23334946)
14. Moorman A.V., Ensor H.M., Richards S.M., et al: Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 11:429-438, 2010
15. Felix C.A., Nau M.M., Takahashi T., et al: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89:640-647, 1992
16. Diccianni M.B., Yu J., Hsiao M., et al: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105-3112, 1994 (Pubitemid 24328104)
17. Blau O., Avigad S., Stark B., et al: Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia. Leuk Res 21:721-729, 1997 (Pubitemid 27458624)
18. Gump J., McGavran L., Wei Q., et al: Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 23:416-419, 2001 (Pubitemid 33031768)
19. Petitjean A., Mathe E., Kato S., et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629, 2007 (Pubitemid 46744292)
20. Kirschner-Schwabe R., Lottaz C., Tödling J., et al: Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia. Clin Cancer Res 12:4553-4561, 2006 (Pubitemid 44297804)
21. Scrucca L., Santucci A., Aversa F.: Competing risk analysis using R: An easy guide for clinicians. Bone Marrow Transplant 40:381-387, 2007 (Pubitemid 47202424)
22. Serra A., Gaidano G.L., Revello D., et al: A new TaqI polymorphism in the p53 gene. Nucleic Acids Res 20:928, 1992
23. Wuchter C., Harbott J., Schoch C., et al: Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia 14:1232-1238, 2000 (Pubitemid 30445030)
24. Harrison C.J., Haas O., Harbott J., et al: Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Münster study group. Br J Haematol 151:132-142, 2010
25. Schwab C.J., Jones L.R., Morrison H., et al: Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 49:1104-1113, 2010
26. Göker E., Waltham M., Kheradpour A., et al: Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86:677-684, 1995
27. Mullighan C.G., Phillips L.A., Su X., et al: Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:1377-1380, 2008 (Pubitemid 352775249)
28. Döhner H., Fischer K., Bentz M., et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
29. Bowen D., Groves M.J., Burnett A.K., et al: TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 23:203-206, 2009
30. Inga A., Cresta S., Monti P., et al: Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis 18:2019-2021, 1997 (Pubitemid 28132390)
31. Venkatachalam S., Shi Y.P., Jones S.N., et al: Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J 17:4657-4667, 1998 (Pubitemid 28377166)
32. Zenz T., Kröber A., Scherer K., et al: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term followup. Blood 112:3322-3329, 2008
33. Momota H., Narita Y., Miyakita Y., et al: Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer 55:577-579, 2010
34. Chompret A., Abel A., Stoppa-Lyonnet D., et al: Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43-47, 2001 (Pubitemid 32102322)
35. Harvey M., Sands A.T., Weiss R.S., et al: In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467, 1993 (Pubitemid 23252375)
36. Kuerbitz S.J., Plunkett B.S., Walsh W.V., et al: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 89:7491-7495, 1992